Now more than ever, enhancing primary care practices to include CGM capabilities is a crucial goal requiring the support and involvement of the broader healthcare community.
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. A validated program that can effectively help people manage their disease is invaluable, especially at a time when in-person physician visits are unavailable.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Through the challenges of the Covid-19 pandemic, caring for whole person health is vital for personal wellness and for business.
Livongo saw its membership and revenue double in the first quarter of 2020, leading into the pandemic. The company also landed a large contract with the Government Employee Health Association, a payer that provides insurance to federal employees.
At Livongo, we have developed and rolled out a targeted coronavirus response effort to keep our Members healthy, informed, and supported through the duration of this pandemic.
Geneia’s Data Intelligence Lab is serving as a test bed for AI and data science tools that reduce healthcare costs through earlier identification and engagement for those at risk of high-cost conditions such as diabetes.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
In an interview, Livongo Chief Commercial Officer Jim Pursley discussed how the company has moved beyond its initial focus of diabetes management to other conditions that may overlap with the needs of its members, such as hypertension and its recent move into behavioral health.
Earlier this year, the company, which raised $3.5 million in 2016, revealed the findings of a three-month study of its technology conducted at Johns Hopkins University.
Insulin prices have shot up nearly 600 percent, according to a congressional study, leading to potentially deadly rationing by many patients.
The company's shares were down more than 40 percent in midday trading as the FDA placed a clinical hold on ZGN-1061, the second such hold the company has experienced in three years.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
In an earnings call last week CVS Health CEO Larry Merlo outlined some of the ways that the company is moving forward on plans to reduce medical costs after its $69 billion purchase of Aetna.
In a deal worth up to $25 million for ViaCyte, the companies will work together to create allogeneic stem cell therapies to treat the disease.
The system has an artificial intelligence algorithm that evaluates the images coming from the camera and determines whether or not there's diabetic retinopathy in them,” explained IDx Founder and President Michael Abràmoff. “So it makes a clinical decision, without someone like me being involved — it's fully autonomous.”
It has raised $2.7 million from six investors, according to a Form D filing with the U.S. Securities and Exchange Commission.
BlueStar requires a prescription from a licensed healthcare provider and can be reimbursed by health plans.